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ABSTRACT
Tamoxifen elevates the risk of endometrial tumours
in women and a-(N
2-deoxyguanosinyl)-tamoxifen
adducts are reportedly present in endometrial
tissue of patients undergoing therapy. Given the
widespread use of tamoxifen there is considerable
interest in elucidating the mechanisms underlying
treatment-associated cancer. Using a combined
experimental and multivariate statistical approach
we have examined the mutagenicity and potential
consequences of adduct formation by reactive inter-
mediates in target uterine cells. pSP189 plasmid
containing the supF gene was incubated with
a-acetoxytamoxifen or 4-hydroxytamoxifen quinone
methide (4-OHtamQM) to generate dG-N
2-tamoxifen
and dG-N
2-4-hydroxytamoxifen, respectively. Plas-
mids were replicated in Ishikawa cells then
screened in Escherichia coli. Treatment with both
a-acetoxytamoxifen and 4-OHtamQM caused a
dose-related increase in adduct levels, resulting in
a damage-dependent increase in mutation fre-
quency for a-acetoxytamoxifen; 4-OHtamQM had
no apparent effect. Only a-acetoxytamoxifen gener-
ated statistically different supF mutation spectra
relative to the spontaneous pattern, with most
mutations being GC!TA transversions. Application
of the LwPy53 algorithm to the a-acetoxytamoxifen
spectrum predicted strong GC!TA hotspots at
codons 244 and 273. These signature alterations
do not correlate with current reports of the muta-
tions observed in endometrial carcinomas from
treated women, suggesting that dG-N
2-tam adduct
formation in the p53 gene is not a prerequisite for
endometrial cancer initiation in women.
INTRODUCTION
Tamoxifen is an anti-oestrogen widely used for the treat-
ment, and more recently chemoprevention of breast
cancer. The use of tamoxifen in healthy women at a
high risk of developing breast cancer is supported by clin-
ical trials demonstrating a 48% reduction in the inci-
dence of oestrogen-receptor-positive breast cancers (1).
Although tamoxifen therapy is relatively well tolerated,
it is associated with a number of serious side eﬀects,
including a 2- to 8-fold increased risk of endometrial
cancer (2,3). The underlying mechanisms of tamoxifen
carcinogenesis in humans are currently undeﬁned. Long-
term administration to rats causes hepatic carcinomas
through a genotoxic mechanism involving activation and
DNA adduct formation (4) and considerable interest is
centred on identifying the role of DNA damage in tamox-
ifen-induced endometrial carcinogenesis.
In rat liver the primary route of tamoxifen adduct for-
mation involves cytochrome P450 CYP3A4-mediated
a-hydroxylation (5) followed by SULT2A1 catalysed
a-sulphation to generate a reactive carbocation that binds
predominantly to deoxyguanosine, forming a-(N
2-deoxy-
guanosinyl)-tamoxifen (dG-N
2-tam) (6,7). a-Hydroxy-
tamoxifen, which can itself react weakly with DNA, is
a circulating metabolite in the plasma of women on
tamoxifen therapy (8). Furthermore, local activation of
both the parent drug and a-hydroxytamoxifen in uterine
tissue is a possibility given the presence of measurable
CYP3A4 protein and SULT2A1 mRNA expression in
this organ (9). More crucially, the potential for tamox-
ifen adduct formation has been demonstrated in lympho-
cytes (10), uterine (11–13) and colon tissue (14) of treated
women, although evidence to the contrary has also been
reported (15,16).
One of the main tamoxifen phase I metabolites,
4-hydroxytamoxifen (4-OHtam), may also be activated
to a DNA reactive species, either via a-hydroxylation or
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chemically or enzymatically activated 4-OHtam with
deoxyguanosine in vitro produces geometric isomers of
a-(N
2-deoxyguanosinyl)-4-hydroxytamoxifen (dG-N
2-4-
OHtam), a 4-hydroxylated version of the major dG-N
2-
tam adduct. Whether this adduct is formed in vivo has not
been clariﬁed, however, dG-N
2-4-OHtam generated by
incubation of 4-OHtam with horseradish peroxidase and
calf thymus DNA, appears to co-elute with a minor hepa-
tic adduct in tamoxifen-treated rats when compared by
HPLC-
32P-post-labelling analysis (18).
Both dG-N
2-tam and dG-N
2-4-OHtam adducts are
established promutagenic lesions; site-speciﬁc studies
in vitro (19) or in COS-7 cells (20) have shown that dG-
N
2-tam primarily directs the misincorporation of dAMP,
resulting in GC!TA transversions. Additionally, we have
previously reported elevated mutation frequencies
when DNA damage generated by 4-OHtamQM and
a-acetoxytamoxifen, a model ester of a-hydroxytamoxi-
fen, is replicated in cultured human ﬁbroblasts and
kidney cells (21,22). The question of whether tamoxifen
adducts are mutagenic in target human endometrial cells
has not yet been addressed.
The presence of characteristic mutation spectra in key
genes isolated from human tumours has been used as evi-
dence of a causal association between exposure to a cer-
tain genotoxic carcinogen, for example UV radiation,
aristolochic acid or aﬂatoxin B1 and cancer initiation
(23–25). As such, this approach is one of the most convin-
cing methods available for demonstrating that agent-
speciﬁc DNA lesions are directly involved in cancer
development. The LwPy53 algorithm (26) utilizes experi-
mental data generated using the supF forward mutation
assay to predict chemical-induced hotspots along the
human p53 gene. The algorithm was recently used to pre-
dict the p53 benzo[a]pyrene diolepoxide (BPDE) mutation
distribution (26), revealing strong mutation hotspots at
codons 157, 248 and 273 that correlate with known pre-
ferential sites of BPDE adduct formation within the p53
gene as well as the major mutation hotspots in lung
tumours of smokers (27).
In order to advance understanding of the biological
signiﬁcance of tamoxifen DNA adduct formation we
have examined the mutagenicity of dG-N
2-tam and dG-
N
2-4-OHtam lesions in human uterine cells. The resulting
spectra were compared to the mutation pattern produced
by tamoxifen administration in the liver of transgenic rats,
to establish the degree of similarity and validate the
approach. Subsequently, the supF data were used to pre-
dict the mutation distribution in the human p53 gene that
might be expected in endometrial tumours of tamoxifen-
treated women if DNA adducts play a role in the early
stages of cancer development.
MATERIALS AND METHODS
Chemicals and reagents
The trans-isomers of a-hydroxytamoxifen and a-acetoxy-
tamoxifen (>99% pure by
1H NMR) were synthe-
sized according to published methods (28). [g-
32P]ATP
(>185 TBq/mmol, >5000Ci/mmol, 370 MBq/ml) was
purchased from Amersham, Buckinghamshire, UK. T4
Polynucleotide kinase (30-phosphatase-free) and calf
spleen phosphodiesterase were bought from Boehringer
Mannheim, Lewes, UK. All other chemicals were from
Sigma, Poole, Dorset, UK, whilst all remaining enzymes
and associated incubation buﬀers were from New England
Biolabs Ltd, Hitchin, UK, unless otherwise stated.
Shuttle vector plasmid, bacterial strainand human cell lines
The plasmid pSP189 containing the supF gene and
Escherichia coli strain MBM7070 (21) were gifts from Dr
M. Seidman (National Institute of Aging, NIH,
Baltimore, MD, USA). Human endometrial adenocarci-
noma (Ishikawa) cells were cultured from cells provided
by Dr Ian White (University of Leicester). Ishikawa cells
were grown in DMEM/F12, phenol red-free (Invitrogen,
Carlsbad, CA, USA) medium supplemented with 10%
fetal calf serum (Life Technologies Ltd, Paisley, UK)
and 2mM GlutaMAX at 378Ci n5 %C O 2 in air.
In vitro methylation ofpSP189 plasmid
Dried pSP189 plasmid (50mg) was methylated in vitro
using 50U of CpG methyltransferase (M.SssI) and
32mM S-adenosylmethionine (5ml) in NEBuﬀer 2
(50mM sodium chloride, 10mM Tris–HCl, 10mM mag-
nesium chloride, 1mM dithiothreitol; pH 7.9at 258C), in
a total reaction volume of 250ml. Following a 2 h incuba-
tion at 378C, the enzyme was heat inactivated at 658C for
20min and methylated pSP189 plasmid was puriﬁed
using Sureclean (Bioline, Bath, UK) before reaction with
a-acetoxytamoxifen or 4-OHtamQM.
To conﬁrm successful methylation of the plasmid prior
to use in adduction reactions, aliquots (2mg) of methy-
lated or unmethylated (control) pSP189 were digested
with 50 U of HpaII in NEBuﬀer 1 (10mM bis-Tris–
propane-HCl, 10mM MgCl2, 1mM dithiothreitol;
pH 7.0 at 258C) in a 60ml reaction volume for 1h at
378C. HpaII does not cleave at restriction sites that have
been CpG methylated by M.SssI but will digest control
pSP189 plasmid within 50-CCGG recognition sites.
Methylation was therefore conﬁrmed by comparing the
reaction products on a 1% agarose gel (data not shown).
Treatment of pSP189 plasmid witha-acetoxytamoxifen
Aliquots of methylated pSP189 plasmid (200mg in 200ml
Tris–EDTAbuﬀer,pH8.0)weretreatedwithvaryingdoses
of a-acetoxytamoxifen dissolved in 100ml 50:50 etha-
nol:acetonitrile (10, 25 and 50mM ﬁnal concentrations)
and the total volume adjusted to 500ml with water.
Samples were prepared in duplicate, along with a single
solvent [ethanol:acetonitrile (50:50)] treated control and
incubated overnight at 378C. Unreacted compound and
degradation products were then extracted with water satu-
rated ethyl acetate (4 400ml) and the DNA precipitated
byaddition of 3M sodium acetate (10ml) andice-cold etha-
nol (800ml). The DNA samples were pelleted by centrifu-
gation and washed with 70% ice-cold ethanol, followed
by 100% ice-cold ethanol. Pellets were then re-dissolved
in 200ml sterile tissue culture grade water.
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4-Hydroxytamoxifen was activated to its quinone methide
as previously described (21). 4-OHtamQM (in 50:50 etha-
nol:acetonitrile) was added to 200mg methylated pSP189
plasmid (in 400mlH 2O) in a total volume of 500ml,
to produce ﬁnal concentrations of 0, 50, 100 and
250mM. After overnight incubation at 378C, unreacted
4-OHtamQM was extracted using water saturated diethyl
ether (5 400ml). Plasmid DNA was then precipitated and
re-dissolved as detailed above.
HPLC-
32P-post-labelling analysis of adducted pSP189
plasmid DNA
To quantify the number of tamoxifen-DNA adducts
formed on the treated plasmids, aliquots of DNA (10mg)
were analysed using our established
32P-post-labelling
assay, with HPLC separation of
32P-post-labelled nucleo-
tides and online radiochemical detection (18). A positive
control sample, liver DNA from a tamoxifen treated
rat, was analysed in parallel to enable adduct identiﬁca-
tion (18,29).
Transfection and transformation
Subconﬂuent Ishikawa cells were transfected with
a-acetoxytamoxifen or 4-OHtamQM treated plasmid
(10mg per 9-cm culture plate) using the Fugene-6 (Roche
Diagnostics Ltd, Lewes, UK) transfection reagent (30ml).
The plasmid was reclaimed from the Ishikawa cells
between 45 and 48h after transfection using plasmid pur-
iﬁcation kits (Qiagen, Crawley, UK). Aliquots were used to
transform electrocompetent MBM7070 E. coli by electro-
poration using Gene Pulser apparatus (Biorad, Hercules,
CA, USA). Transformants were plated onto LB agar plates
containing ampicillin (100mg/ml), 5-bromo-4-chloro-
3-indolyl-b-D-galactose (X-gal) (75mg/ml) and isopropyl-
b-D-thiogalactoside (IPTG) (25mg/ml). Mutant colonies
were white when grown on X-gal containing media,
whereas wild-type colonies were blue.
Sequencing
Plasmid derived from mutant colonies was ampliﬁed with
the TempliPhi
TM DNA Sequencing Template Ampliﬁca-
tion Kit (GE Healthcare, Buckinghamshire, UK) before
DNA sequencing. A primer with the sequence 50-GGCGA
CACGGAAATGTTGAA-30 (biomers.net GmbH, Ulm,
Germany) was used for all sequencing reactions after pur-
iﬁcation on a 20% denaturing PAGE gel and sequencing
was performed by the Protein and Nucleic Acid Chemistry
Laboratory, University of Leicester (Leicester, UK). Any
mutant with a duplicated ‘signature’ was excluded from
further analysis and Poisson distribution analysis was used
to assess the randomness of spectra (21,22).
Comparison of spectra
Benzo[a]pyrene, UVB, UVC and simulated sunlight-
induced base substitution data were obtained from the
literature for the cII gene in the Big Blue mouse transgenic
model, and the supF gene in XP-A ﬁbroblast or the human
kidney Ad293 cell lines (30–34). In addition, data for
BPDE, UV/simulated sunlight and hydroxyl radicals
acquired using the yeast p53 functional mutation assay
were included (33,35,36). Mutation data for tamoxifen
and its metabolite a-hydroxytamoxifen in the cII sequence
of liver tissue isolated from Big Blue transgenic rats was
taken from Davies et al. (37) and Chen et al. (38), respec-
tively. Mutation signatures were created for each spectrum
using the approach described by Lewis et al. (33). This
method transforms base substitution spectra into a stan-
dardized format allowing direct comparison of spectra
from diﬀerent DNA sequences. The method captures
sequence context and mutation type information simulta-
neously. Hierarchical cluster analysis (HCA) was then
applied to the transformed mutation signatures to explore
the similarities between spectra. A similarity matrix was
generated by Euclidean distance, which served as input to
the average linkage tree building algorithm. The method
presents a hierarchical tree or dendrogram as a visualiza-
tion aid to determine similarities between signatures.
Application ofthe LwPy53 algorithm
The LwPy53 algorithm was developed previously to utilize
mutagen-induced GC!AT transition data in the supF
gene to predict mutation hotspots in exons 5, 7 and 8 of
the human p53 gene. The algorithm, described fully in
Lewis and Parry (26), has been modiﬁed to account for
all base substitution types. LwPy53 takes as input a supF
base substitution spectrum and combines this information
with parameters representing mutation selection, DNA
curvature and nucleosome positioning within the p53
gene. Extrapolation of mutation sequence context from
supF to p53 is based on the relative mutability of dinucleo-
tides. The algorithm produces as output a distribution of
mutation hotspots that would be predicted if the p53 gene
were exposed to the mutagen. In each resulting spectrum,
mutation sites are represented as a percentage of the total
number of predicted mutations. We applied LwPy53 to
the a-acetoxytamoxifen combined spectrum (25mM plus
50mM) to generate predicted p53 mutation spectra.
RESULTS
Tamoxifen-DNA adduct quantification
by
32P-post-labelling
The shuttle vector plasmid pSP189 was modiﬁed by
reaction with a-acetoxytamoxifen or 4-OHtamQM and
aliquots were subjected to HPLC-
32P-post-labelling ana-
lysis to quantify the adduct levels formed. The concentra-
tions used were chosen on the basis of our previous studies
in Ad293 kidney cells (21), which found that treatments
with a-acetoxytamoxifen in the range 10–50mM were
required to generate signiﬁcantly mutagenic levels of
damage, whilst higher concentrations of 4-OHtamQM
(50–250mM) were necessary due to this derivative forming
lower adduct numbers per molar equivalent. The adduct
proﬁles induced by the two compounds were comparable
with our previous report in which the pSP189 plasmid
employed was used directly after isolation from E. coli
(21) and therefore contained the Dam methylation pattern
rather than mammalian CpG methylation. The rationale
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based on the fact the p53 gene is methylated in a variety
of human tissues and many chemical carcinogens exhibit
a preference for binding at methylated CpG sites.
Furthermore, the LwPy53 algorithm has been shown cap-
able of predicting the p53 mutation spectrum in lung can-
cers from smokers using BPDE derived supF data in
methylated plasmid, whereas there was no such correla-
tion when unmethylated plasmid was used (26). The pre-
sent ﬁndings indicate that the presence of CpG
methylation does not overtly aﬀect the types and propor-
tions of speciﬁc adducts formed (18,21). Treatment of
plasmid with a-acetoxytamoxifen resulted in the forma-
tion of one major peak (Figure 1B) consistent with
the dG-N
2-tam adduct detected in hepatic DNA
from a tamoxifen-treated rat (Figure 1D). An additional
minor peak is also observed eluting just prior to the
major adduct, which has previously been suggested
to be a diastereoisomer of trans-dG-N
2-tamoxifen (29).
Following incubation of 4-OHtamQM with plasmid
DNA, two main
32P-post-labelled adduct peaks are
detected, presumably cis- and trans-isomers of dG-N
2-4-
OHtam (Figure 1C) (17). Both of these adducts have simi-
lar chromatographic properties to minor DNA adduct
peaks found in the rat liver tissue (Figure 1D).
As expected, for both reactive derivatives adduct
levels increased with increasing concentration in a dose-
dependent manner (Figure 2A). For the same
exposure (50mM) 4-OHtamQM induced a 95-fold lower
level of tamoxifen DNA adducts per plasmid than
a-acetoxytamoxifen. Based on a plasmid size of 4952bp
the degree of pSP189 modiﬁcation by a-acetoxytamoxifen
equates to a level of 1.8, 3.0 or 3.8 adducts per plasmid for
the 10, 25 and 50mM doses, respectively. In comparison,
the three treatments with 4-OHtamQM (50, 100 and
250mM) induced  0.04, 0.08 and 0.31 adducts per plas-
mid, damage levels that have previously proven highly
mutagenic.
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Figure 1. Representative HPLC chromatograms of
32P-post-labelled DNA digests from untreated solvent control plasmid (A) or plasmid samples
incubated with a-acetoxytamoxifen (B) or 4-hydroxytamoxifen quinone methide (C), and liver DNA from a tamoxifen-treated Wistar Han rat
(40mg/kg tamoxifen in the diet for 6 months) (D). The amount of DNA injected was 9.1mg for all samples except the a-acetoxytamoxifen adducted
plasmid (0.5mg).
5936 Nucleic Acids Research, 2008, Vol. 36, No. 18Mutation frequency insupF gene
As illustrated in Figure 2B, upon replication in Ishikawa
cells a-acetoxytamoxifen-induced DNA adducts caused a
dose-dependent increase in mutation frequency relative to
the solvent control (3.1-fold higher for 10mM, 10.5-fold for
25mM and 18.4-fold for 50mM). In contrast, no such dose
or damage-related eﬀect was apparent with 4-OHtamQM-
treated plasmid. In this case, the highest mutation fre-
quency was evident in plasmid treated with 100mM
4-OHtamQM (9.6/10
4 colonies); however, this was only
1.96-fold higher than the spontaneous mutation frequency
in the solvent control plasmid and equates to a weak, if
any, mutagenic eﬀect. Overall, a-acetoxytamoxifen-
treated plasmid generated 631 mutant colonies out of a
total of 246494, whilst 4-OHtamQM produced 290
mutants out of 375301 colonies. Similar numbers of
mutant colonies for each treatment ( 200) were then
sequenced to generate mutation spectra.
Mutation typein thesupF gene
White mutant colonies were collected and the supF gene
sequenced to identify the types and location of mutations.
The majority of mutations resulting from replication
of both a-acetoxytamoxifen and 4-OHtamQM-induced
damage were base substitutions (79 and 63% of all
mutants, respectively). For a-acetoxytamoxifen, most of
these were in the form of single base alterations (90%),
with a few tandem (2%) and a larger proportion of multi-
ple substitutions (8%; two or more substitutions at
non-adjacent sites along the supF gene). In mutant colo-
nies derived from 4-OHtamQM-treated plasmid, single
substitutions were again predominant (78% of all substi-
tutions), followed by multiple (16%) and tandem (6%)
substitutions.
Small frameshifts were a relatively infrequent conse-
quence of both a-acetoxytamoxifen and 4-OHtamQM-
induced damage, detected in just 9 and 3% of mutant
plasmids, respectively. When present, the majority of fra-
meshifts in a-acetoxytamoxifen-treated plasmid took the
form of single base deletions accounting for 68% of the
total, while single base insertions were more common
(67% of all frameshifts) in 4-OHtamQM-treated plasmid.
Interestingly, a large deletion of bases 97!267 (including
the whole supF gene) was present in 40% of the combined
control mutants sequenced, 12% of a-acetoxytamoxifen
and 33% of 4-OHtamQM-treated plasmids. The occur-
rence of this large 171-bp deletion decreased markedly
upon exposure to a-acetoxytamoxifen, accounting for
29, 9 and 1% of all mutations in the 10, 25 and 50-mM-
treated plasmids respectively, as the proﬁle is less inﬂu-
enced by spontaneous alterations and becomes more
characteristic of a-acetoxytamoxifen. The nature of this
background mutation is uncertain, although there is
strong evidence it is related to short direct repeats that
mediate deletions and duplications in DNA (39,40). Two
possible mechanisms for these events are recombination
between short homologous repeats and DNA polymerase
slippage between short repeated sequences. Short-homol-
ogy-independent illegitimate recombination (41) requires
short regions of homology between recombination sites
such as the 5-bp sequence (GAGCT) in the junction of
the 171-bp deletion observed in the present study.
Figure 3 illustrates the eﬀect of increasing dose and
adduct level on the single base substitution proﬁles
induced by a-acetoxytamoxifen and 4-OHtamQM. Each
type of substitution is expressed as a percentage of the
total substitutions detected for each dose. For a-acetoxy-
tamoxifen-modiﬁed plasmid (Figure 3A), the increasing
dose is mirrored by an increase in the proportion of
GC!TA transversions, which become the predominant
substitution beyond 10mM. At the same time, the pro-
portion of GC!AT transitions, the alteration that
dominates the spontaneous spectrum, decreases with
dose. The mutation pattern produced by replication of
a-acetoxytamoxifen adducted plasmid in human endome-
trial cells is consistent with that resulting from replication
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Figure 2. Dose–response relationships for DNA adduct formation and
mutation induction. DNA adduct levels in plasmid treated with a-acet-
oxytamoxifen (dashed line) and 4-OHtamQM (solid line) determined by
HPLC-
32P-post-labelling analysis (A). Data represent the mean SD of
duplicate measurements of two plasmid samples per dose. For each
chart the 0mM dose represents control pSP189 plasmid incubated
with solvent only. The lower chart illustrates the relationship between
mutation frequency and DNA adduct level for damage induced by
a-acetoxytamoxifen and 4-OHtamQM, with the insert corresponding
to a magniﬁcation of the 4-OHtamQM data (B). The mutation fre-
quency of control plasmid suspended in water only was 7.2/10
4 colo-
nies, which is comparable to that observed for plasmid incubated with
solvent, 4.9/10
4 colonies. The presence of ethanol:acetonitrile (50:50)
was therefore adjudged to have no appreciable eﬀect on spontaneous
mutagenesis and data from both types of control were combined to
increase the pool of mutated colonies for subsequent sequence analysis.
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2-tam in several other cellular systems and can be
considered characteristic of the damage present (20–22). In
contrast, there is little obvious diﬀerence between the var-
ious 4-OHtamQM treatments, with the most frequent
single base substitution being GC!AT transitions at all
concentrations. Furthermore, the overall substitution pro-
ﬁle for 4-OHtamQM adducted plasmid was virtually indis-
tinguishable from that observed in spontaneous mutants
derived from untreated control plasmid (Figure 3B).
AnalysisofmutationspectrainthesupFandhumanp53genes
The distribution of single base and tandem substitution
mutations within the supF gene for plasmids treated with
either a-acetoxytamoxifen (25 and 50mM combined) or
4-OHtamQM (50, 100 and 250mM combined) is shown
in Figure 4. When these spectra are compared to the
untreated control spectrum, which is comprised of spon-
taneous mutations using the Adams–Skopek hypergeo-
metric test (42), only the a-acetoxytamoxifen spectrum is
found to be signiﬁcantly diﬀerent (P=0.00006). Within
the mutation spectrum induced in control plasmid there
are three hotspots at positions 129, 133 and 139. In the
a-acetoxytamoxifen combined spectrum six hotspots are
evident at positions 115, 122, 129, 159, 160 and 168, all of
which are at GC sites, consistent with guanine being the
primary site of tamoxifen adduction. Five hotspots are
apparent in the spectrum of single base substitutions
induced by 4-OHtamQM, at positions 108, 129, 133, 139
and 168, all at sites of GC basepairs. Only one hotspot at
position 129 was shared between the a-acetoxytamoxifen
and control spectra, whereas all three control hotspots
(at positions 129, 133 and 139) also appear in the
4-OHtamQM spectrum. One further hotspot (position
168) was common to both the a-acetoxytamoxifen and
4-OHtamQM spectra.
Only a-acetoxytamoxifen exposure resulted in an
increased mutation frequency and a spectrum signiﬁcantly
diﬀerent from the spontaneous pattern. Therefore, these
data alone (25 and 50mM doses combined) were used for
subsequent analyses. Using HCA comparisons can be
made between multiple carcinogen-induced mutation
spectra produced in diﬀerent experimental systems,
regardless of sequence (33). Adopting this approach the
pattern and type of mutations observed in the present
study with a-acetoxytamoxifen were compared with base
substitutions generated in the cII gene isolated from liver
tissue of tamoxifen and a-hydroxytamoxifen-treated Big
Blue transgenic rats (37,38). In addition, comparisons
were made with mutation spectra induced by exposure
to UVB, UVC, simulated sunlight, BPDE or hydroxyl
radicals in the cII, supF and yeast p53 model systems
(30–36). Results revealed a high degree of similarity
between the three tamoxifen spectra, which all grouped
closely together forming a separate subcluster (Figure 5).
Furthermore, the tamoxifen mutational signature was dis-
tinct from that caused by the other mutagens, which also
clustered according to the speciﬁc chemical or exposure,
independently of the assay system employed.
The LwPy53 algorithm was then applied to the
a-acetoxytamoxifen supF data to predict the distribution
of mutations that might be expected to arise in the human
p53 gene as a consequence of dG-N
2-tam adduct forma-
tion in endometrial tissue. Hypothetical treatment with
a-acetoxytamoxifen produced two GC!TA hotspots in
the human p53 gene at codons 244 and 273 of exons 7
and 8, respectively (Figure 6).
DISCUSSION
Evidence suggests tamoxifen is capable of forming DNA
adducts in the endometrial tissue of treated women, albeit
at low levels and with a degree of inter-individual varia-
bility. Since little is understood about the actual role of
tamoxifen adduct formation in endometrial cancer devel-
opment, the primary aim of this work was to investigate
the mutagenicity and potential biological consequences of
tamoxifen adducts in this target tissue. The supF gene has
been used as target for mutagenesis by a wide variety of
mutagens but virtually all of the work to date has been
performed using non-CpG methylated plasmid. By methy-
lating the pSP189 plasmid in vitro prior to tamoxifen
adduction we were able to exploit the LwPy53 algorithim
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Figure 3. Bar charts illustrating the proportion of diﬀerent single base
and tandem substitution mutations observed in combined control plas-
mid (solvent and water controls combined) and in plasmid treated with
a-acetoxytamoxifen (10, 25 and 50mM) (A) or 4-OHtamQM (50, 100
and 250mM) (B).
5938 Nucleic Acids Research, 2008, Vol. 36, No. 18Figure 4. Mutation spectra depicting single base and tandem substitutions in the supF gene induced in human endometrial cells by a-acetoxytamoxifen
(25 and 50mM) and 4-hydroxytamoxifen quinone methide (50, 100 and 250mM). The 5–30 sequence of the transcribed strand of the wild-type supF gene is
shown, with letters below the wild-type sequence indicating the position and type of point mutations induced by treatments and the letters above the wild-
type sequence showing the position and type of point mutations induced in the combined control sample. Hotspots (represented by asterisks) are assumed
when the number of mutations observed is 4-fold or more greater than the number expected for a random (Poisson) distribution (21,22). Tandem
mutations are underlined.
Nucleic Acids Research, 2008, Vol. 36, No. 18 5939for the prediction of GC!TA transversion hotspots along
exons 5, 7 and 8 of the human p53 gene in response to
a-acetoxytamoxifen treatment.
CpG methylation of the pSP189 plasmid DNA prior
to incubation with the model reactive metabolites
a-acetoxytamoxifen and 4-OHtamQM had no obvious
eﬀect on gross adduct number or the general proﬁle of
damage induced, as assessed by HPLC-
32P-post-labelling.
Tamoxifen adducts were formed in a dose-dependent
manner, with levels ranging from 175 to 376 and 4 to 30
adducts/10
6nt for a-acetoxytamoxifen and 4-OHtamQM,
respectively, which are similar to that produced in non-
methylated plasmid (50–240 and 5–20/10
6nt) using iden-
tical concentrations in our previous studies (21,22). It is
however quite feasible that although the degree of
adduction was unaﬀected, positions of adduct formation
along the supF gene or lesion conformation may be inﬂu-
enced by CpG methylation and this alone may be suﬃ-
cient to signiﬁcantly alter mutagenic outcome (43,44).
Replication of a-acetoxytamoxifen induced damage in
human endometrial cells resulted in a dose-related increase
in mutation frequency (Figure 2B). This elevation was
apparent from the lowest dose (10mM), where the relative
mutation frequency was treble the spontaneous rate in
solvent treated plasmid and it reached a maximum of
18.4-fold above background at the 50mM concentration.
The mutagenic potency of a-acetoxytamoxifen-derived
damage in endometrial cells is greater than in both human
kidney cells and ﬁbroblasts, when compared in terms of
relative mutation frequency for a given adduct level.
A
B
Code Mutagen Gene Tissue origin/Test system Reference
UBs UVB  supF XP-A fibroblast/supF assay  34
UCy2 UVC  p53  Yeast p53 functional assay  35
SUNc Simulated sunlight cII Fibroblast/Big Blue mouse  32
UCs UVC  supF Human kidney/supF assay  33
UCy1 UVC  p53  Yeast p53 functional assay  36
UBc UVB  cII Embryonic fibroblasts/Big Blue mouse  31
UCc UVC  cII Fibroblast/Big Blue mouse  32
Tc α-Hydroxytamoxifen  cII Liver/Big Blue rat  38
Ts α-Acetoxytamoxifen  supF Human endometrium/supF assay  Present study 
Tc2 Tamoxifen  cII  Liver/Big Blue rat  37
BPy2 Benzo[a]pyrene  p53  Yeast p53 functional assay  35
BPc Benzo[a]pyrene  cII Embryo fibroblast/Big Blue mouse  30
OH Hydroxyl radical  p53  Yeast p53 functional assay  33
BPy1 Benzo[a]pyrene  p53  Yeast p53 functional assay  33
BPs Benzo[a]pyrene  supF XP-A fibroblast/supF assay  30
Figure 5. HCA dendrogram to reveal similarities between transformed mutation signatures. The UV-induced mutation signatures group separately
form a cluster containing the remaining signatures due to a predominance of the GC!AT mutation type. However, in the second cluster the three
tamoxifen signatures in the supF and cII genes form their own, distinct subcluster. This subcluster demonstrates that the tamoxifen spectra are very
similar in sequence context and mutation type (A). Table describing details of the mutation spectra used (B).
5940 Nucleic Acids Research, 2008, Vol. 36, No. 18Replication of just 3.0 lesions per plasmid caused a 10.5-
fold increase in mutation frequency in endometrial cells,
whilst 2.5 and 3.4 adducts per plasmid resulted in a 5-and
1.2-fold increase in kidney and ﬁbroblast cells respectively
(21,22). Comparison of the a-acetoxytamoxifen induced
supF mutation spectrum (Figure 4) with results obtained
in kidney cells and repair proﬁcient ﬁbroblasts (21,22)
using the Adams–Skopek test revealed both published
spectra, which were derived from unmethylated plasmid,
to be signiﬁcantly diﬀerent from that produced in endome-
trial cells. Therefore, whilst it is possible that CpG methy-
lation of the plasmid used in the present study is
contributing to the enhanced eﬀect, the results suggest
that the major dG-N
2-tamoxifen adduct, which is already
considered to be a potent mutagenic lesion (21), poses an
even higher mutation risk in endometrial cells. Previously
published supF studies with bulky carcinogens have
reported lower levels of mutagenicity. Speciﬁcally, when
compared on an adduct per plasmid basis, a-acetoxyta-
moxifen is about 39 times more mutagenic than benzo[c]-
phenanthrene (45), 22-fold more mutagenic than
1,6-dinitropyrene (46) and 9–18 times more mutagenic
than BPDE-derived damage (47,48).
The prevalent spontaneous substitution mutation in
control plasmids were GC!AT transitions, consistent
with previously reported supF mutation spectra in human
Ad293 cells (49), lymphoblasts (50) and monkey kidney
cells (51). The introduction of increasing levels of a-acet-
oxytamoxifen-induced damage causes a clear dose-depen-
dent shift towards GC!TA transversions, which become
the predominant mutation beyond 10mM (Figure 3A) and
the proportion of total mutations caused by spontaneous
events decreases. Lower, but signiﬁcant levels of GC!AT
transitions are also still observed at the higher doses. Site-
speciﬁc mutation studies in COS-7 cells (20), previous supF
experiments (21,22), primer extension reactions in vitro
(19,52) and in vivo studies with tamoxifen treated trans-
genic rats (53) have established GC!TA transversion
mutations as the primary misincorporation product of
translesion synthesis past dG-N
2-TAM adducts, with
GC!AT transitions also apparent under certain circum-
stances. The present results therefore conﬁrm GC!TA
mutations as being characteristic of damage induced by
a-acetoxytamoxifen and by inference, a-hydroxytamoxifen
and a-sulphatetamoxifen (if formed), in human endome-
trial cells.
Comparison of mutation spectra constructed from
sequence analysis of spontaneous and treatment-induced
mutant plasmids using the Adams–Skopek test, revealed
that the single and tandem base substitution spectra from
the two top a-acetoxytamoxifen doses (25 and 50mM)
were statistically diﬀerent from the combined control
(P<0.05). These were therefore combined into a single
spectrum with a total of six hotspots evident, at positions
115, 123, 129, 159, 160 and 168. Hotspots at base pairs
numbered 159 and 160 were also observed in the mutation
spectrum arising from replication of a-acetoxytamoxifen
induced damage in Ad293 kidney cells (21), whilst those at
positions 115, 123 and 168 also seem to be characteristic of
this treatment by virtue of the fact they were not detected
in the control spectra. Position 129 was a hotspot in all
a-acetoxytamoxifen and untreated control spectra, except
for the top a-acetoxytamoxifen dose (50mM). A single
hotspot at the same position (129) was the only one
observed in a previously reported supF spontaneous spec-
trum generated in Ad293 cells, suggesting alterations here
may be induced by a-acetoxytamoxifen or could be due to
background endogenous damage (49). Two other hotspots
(133 and 139) were present in the combined control spec-
trum and were not observed in any a-acetoxytamoxifen
induced spectra, implying these mutations arose purely
through spontaneous means. This conclusion is further
supported by a recent comparative analysis of mammalian
cell line spontaneous mutation spectra in supF (54), in
which hotspot C133 was the most frequent and hotspots
at G129 and C139 were also common.
It is interesting that compared to the clear mutagenicity
of a-acetoxytamoxifen-derived adducts, treatment of
methylated pSP189 with 4-OHtamQM failed to convin-
cinglyraisethemutationfrequencyabovebackgroundcon-
trol levels; absolute mutation frequencies were only slightly
higher than the spontaneous value of 4.9/10
4 colonies and
were unrelated to dose. This ﬁnding is in sharp contrast to
the mutation frequencies reported in our analogous supF
investigation of 4-OHtamQM in Ad293 cells (21), which
revealed 4-OHtamQM induced damage to be  25 times
more mutagenic than a-acetoxytamoxifen-derived adducts
on an adduct per plasmid basis. Although the reason(s)
behind the speciﬁc lack of mutagenicity in endometrial
cells is unclear, there are several possible explanations.
Importantly, identical protocols for the synthesis of
4-OHtamQM and plasmid adduction were adopted in
each study and the levels of adducts detectable by
32P-
post-labelling were remarkably similar, which indicates
the diﬀerence in mutagenicity cannot be attributed to var-
iations in the extent of dG-N
2-4-OHtam adduct formation.
However,theuseofCpGmethylatedplasmidinthepresent
study could inﬂuence the overall damage proﬁle.
Whilst there was no obvious diﬀerence in the adduct pat-
tern detected by
32P-post-labelling, we have previously
ascribed the induction of relatively high numbers of
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Figure 6. Predicted human p53 GC!TA mutation spectrum for exons
5, 7 and 8 from data generated using methylated supF plasmid treated
with a-acetoxytamoxifen. A mutation site is classed as a hotspot (desig-
nated asterisk) if the nucleotide contains at least 5% of the total
number of mutations. The vertical axis shows the percentage of base
substitutions for each site relative to the overall number of substitutions
in the spectrum.
Nucleic Acids Research, 2008, Vol. 36, No. 18 5941multiple mutations and large deletions in 4-OHtamQM-
treated plasmid to the presence of dimer adduct cross-
links or free radical induced strand breaks, both of which
would probably be undetectable by the
32P-post-labelling
assay employed (21). DNA methylation at CpG sites could
potentially reduce the likelihood of dimer formation and
may also alter the conformational and/or miscoding prop-
erties of any resulting dG-N
2-4-OHtam adducts or cross-
links, rendering the damage less mutagenic. Finally, cell
speciﬁc factors (e.g. diﬀerent polymerase proﬁles) could
contribute to, or even account entirely for, the diﬀerent
mutagenic processing of 4-OHtamQM-derived lesions in
endometrial cells (55).
Consistent with the lack of mutagenic activity, the pro-
ﬁle of single-tandem and multiple substitutions generated
by 4-OHtamQM was similar to the types of spontaneous
mutations observed in the control plasmid (Figure 3B).
Furthermore, the 4-OHtamQM mutation spectra were
statistically similar to the untreated control spectra
(P>0.05), sharing three hotspots (at positions 129, 133
and 139) in the combined single-tandem spectrum
(Figure 4). Taken together, the evidence suggests that
replication of 4-OHtamQM-induced damage in human
endometrial cells has no real eﬀect on the background
spontaneous mutagenicity and implies any compound spe-
ciﬁc lesions generated by 4-hydroxytamoxifen do not play
a major role in tamoxifen-induced cancers.
Recently, we have described a novel strategy for com-
paring mutation spectra in a variety of genes generated in
diﬀerent in vitro/in vivo assay systems, which creates muta-
tional signatures by capturing mutation type and sequence
context information simultaneously (33). This methodol-
ogy was exploited to assess the validity of using tamoxifen
supF data to predict in vivo spectra. Interestingly, HCA
revealed a strong similarity between mutational signatures
for tamoxifen in the supF and cII genes, clearly distinct
from that produced by other genotoxic agents BPDE,
speciﬁc types of UV radiation and hydroxyl radicals.
Importantly, these ﬁndings strongly support the use of
in vitro supF data for the prediction of in vivo mutation
spectra in situations where tamoxifen acts as a genotoxic
carcinogen, as is the case in rat liver. Furthermore, the
results reinforce the theory that if tamoxifen adduct for-
mation in the p53 gene is a factor in endometrial cancer
development, a characteristic pattern of mutations, distin-
guishable from that induced by other DNA adducts,
might be expected.
Missense mutations in the gene sequence encoding the
DNA-binding domain (exons 5–8) of p53 are found in
 50% of human cancers (56). These alterations result in
nuclear accumulation of p53 protein with loss of normal
functions. Mutations in the p53 gene are an important
early event in the initiation of many types of cancer, mean-
ing that for some tumours arising through genotoxic
mechanisms, signature patterns of p53 mutations may be
matched aetiologically with exposure to speciﬁc carcino-
gens (57). The majority (>80%) of sporadic endometrial
carcinomas is classed as oestrogen-driven, Type I tumours
with a good overall prognosis which are characterized by
mutations in PTEN, PIK3CA, b-catenin and K-ras, but
not in p53. In comparison, the less frequent Type II
non-oestrogen-related carcinomas are high-grade with a
worse prognosis and exhibit chromosomal instability
and p53 mutations (58). There is mounting evidence to
suggest that tamoxifen exposure increases the risk of
developing type II tumours with unfavourable histological
features. These more aggressive tumours seem to occur in
women diagnosed years after discontinuation of tamoxi-
fen therapy, whilst Type I tumours are more likely to
develop in women during treatment (59). This is consistent
with two distinct mechanisms: the oestrogen agonist activ-
ity of tamoxifen accounting for Type I tumours whilst a
genotoxic hormone independent mechanism involving
DNA adduct formation could contribute to the develop-
ment of Type II tumours (59,60).
Based on the p53 GC!TA transversion predictions,
treatment with a-acetoxytamoxifen generates two hot-
spots at positions 244 and 273. Position 273 in the
DNA-binding region of p53 appears to be a common hot-
spot for bulky adducts, such as those formed by benzo[a]-
pyrene, a component of tobacco smoke (61). Overall,
codon 273 in exon 8 is one of the most frequently mutated
sites in human tumours and resides within regions of slow
DNA repair (62). Alteration of this important amino acid
residue, which forms contacts between the protein struc-
ture and DNA, has a detrimental eﬀect on the ability of
p53 to act as a transcription factor in the activation of
downstream genes. The predominant mutations occurring
at this site in human tumours are GC!AT transitions.
However, as is predicted for tamoxifen in the present
study, benzo[a]pyrene exposure induces characteristic
GC!TA transversions at codon 273, which enables
tobacco-related cancers to be distinguished from sponta-
neous lung tumours (63). Codon 244 of exon 7 is far less
frequently mutated in human cancers, therefore it could
potentially provide a speciﬁc signature mutation for
tamoxifen-induced endometrial carcinomas.
There is very limited published data on the p53 muta-
tion distribution in endometrial tumours occurring in
women undergoing tamoxifen therapy and in carcinomas
arising spontaneously. Very recently Fujiwara et al. (64)
reported the presence of characteristically unique p53
mutation spectra in endometrial carcinomas from tamox-
ifen-treated women. Of the 23 samples screened, six (26%)
contained p53 mutations; four substitutions in exons 5 and
6 (two GC!AT at non-CpG sites, one AT!CG, one
AT!GC) and two insertions (both TGT!TGTT at
codon 238) were detected. This proﬁle diﬀered consider-
ably from the pattern previously described in sporadic
endometrial carcinoma by the same group, where GC!
AT mutations were present in 45% of cases, all at methy-
latable CpG sites (65). Although the number of mutations
observed are low, the fact that none occurred at codons
244 or 273, or corresponded to the expected GC!TA
alterations preferentially induced by dG-N
2-tam, suggests
that tamoxifen adducts are not directly involved in the
generation of p53 mutations in treated women. It is recog-
nized however, that for a more deﬁnitive conclusion many
more tamoxifen-associated endometrial tumours need to
be screened for mutations. The individual spectra gener-
ated in this study, and those used by Lewis et al. (33) for
other genotoxic agents such as BPDE, each contain at
5942 Nucleic Acids Research, 2008, Vol. 36, No. 18least 20 mutable sites with over 70 mutations distributed
across these sites. This means that the estimated power for
any pairwise comparisons of these spectra would be high
(66). For example, a test where both spectra contributed a
total of 150 mutations across 20 mutable sites would have
an estimated power of  84%. It is currently not appro-
priate to make such comparisons with the p53 spectrum in
endometrial carcinomas from tamoxifen-treated women
described by Fujiwara et al. (64) as statistical power
would be lacking; the in vivo data would contribute only
six mutations, giving a relatively low overall mutation
count and power estimated to be considerably <50%.
By employing a combined experimental and multivari-
ate statistical approach, further insight into the role of
tamoxifen-induced DNA damage in endometrial carcino-
genesis has been gained. The results support the use of
supF data for predicting in vivo mutation spectra.
Therefore, considering the lack of correlation between
the hypothetical p53 mutation spectrum and alterations
reported to date in endometrial tumours, it seems that
although they may be characteristic of treatment, the
mutations are unlikely to be caused by misincorporation
opposite dG-N
2-tam lesions. Accordingly, based on cur-
rent evidence dG-N
2-tam adduct formation, at least in the
p53 gene, does not appear to be a prerequisite for endo-
metrial cancer initiation in women.
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